NCT07051447View on ClinicalTrials.gov

The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

February 1, 2029

Study Completion Date

August 1, 2029

Conditions
End Stage Kidney Disease
Interventions
OTHER

PKRxHD

The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).

PROCEDURE

Dialysis

Standard of care dialysis.

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

NYU Langone Health

OTHER

NCT07051447 - The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial | Biotech Hunter | Biotech Hunter